Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Friday, November 10th. They presently have a $21.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential downside of 5.49% from the company’s previous close.
Several other research firms also recently weighed in on CNCE. Stifel Nicolaus reissued a “buy” rating and set a $30.00 price target on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. Zacks Investment Research downgraded Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Mizuho assumed coverage on Concert Pharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $23.00 price objective for the company. BidaskClub downgraded Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $23.00.
Shares of Concert Pharmaceuticals (NASDAQ:CNCE) traded up $0.06 during mid-day trading on Friday, reaching $22.22. The company had a trading volume of 194,500 shares, compared to its average volume of 239,669. Concert Pharmaceuticals has a 52-week low of $7.11 and a 52-week high of $22.59.
ILLEGAL ACTIVITY WARNING: “Concert Pharmaceuticals’ (CNCE) “Buy” Rating Reaffirmed at HC Wainwright” was originally published by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/concert-pharmaceuticals-cnce-buy-rating-reaffirmed-at-hc-wainwright/1775482.html.
In other Concert Pharmaceuticals news, insider Value Fund L. P. Biotechnology purchased 331,916 shares of the business’s stock in a transaction that occurred on Thursday, October 19th. The shares were acquired at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ryan Lynch sold 3,500 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $14.51, for a total value of $50,785.00. Following the completion of the transaction, the insider now owns 9,500 shares in the company, valued at approximately $137,845. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the stock. American International Group Inc. increased its holdings in Concert Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,156 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 677 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Concert Pharmaceuticals during the third quarter valued at approximately $153,000. Alliancebernstein L.P. bought a new position in shares of Concert Pharmaceuticals during the second quarter valued at approximately $174,000. State of Wisconsin Investment Board bought a new position in shares of Concert Pharmaceuticals during the second quarter valued at approximately $181,000. Finally, Princeton Capital Management Inc. bought a new position in shares of Concert Pharmaceuticals during the third quarter valued at approximately $215,000. 60.97% of the stock is owned by hedge funds and other institutional investors.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.